In vitro characterization of a multifunctional staphylokinase variant with reduced reocclusion, produced from salt inducible E. coli GJ1158
K K Pulicherla, Anmol Kumar, G S Gadupudi, Seetha Ram Kotra, K R S Sambasiva Rao, K K Pulicherla, Anmol Kumar, G S Gadupudi, Seetha Ram Kotra, K R S Sambasiva Rao
Abstract
The thrombolytic therapy with clinically approved drugs often ensues with recurrent thrombosis caused by thrombin-induced platelet aggregation from the clot debris. In order to minimize these problems, a staphylokinase (SAK)-based bacterial friendly multifunctional recombinant protein SRH (staphylokinase (SAK) linked with tripeptide RGD and dodecapeptide Hirulog (SRH)) was constructed to have Hirulog as an antithrombin agent and RGD (Arg-Gly-Asp) as an antiplatelet agent in the present study. This multifunctional fusion protein SRH was expressed in osmotically inducible E. coli GJ1158 as soluble form and purified with a yield of 0.27 g/L and functionally characterized in vitro. SRH retained the fibrinolytic activity and plasminogen activation rate comparable to the parental counterpart SAK. The antithrombin activity of SRH was significantly higher than SAK. The platelet rich clot lysis assay indicated that SRH had enhanced platelet binding activity and T(50%) and C50 of SRH were significantly lower than that of SAK. Furthermore, SRH inhibited the ADP-induced platelet aggregation in dose-dependent manner while SAK had no significant effect on platelet aggregation. Thus, the current study suggests that the SAK variant produced from osmotically inducible GJ1158 is more potent thrombolytic agent with antithrombin and antiplatelet aggregation activities for reduction of reocclusion in thrombolytic therapy.
Figures
References
- Nichols M, Townsend N, Scarborough P, et al. European Cardiovascular Disease Statistics 2012. Brussels, Belgium: European Heart Network, European Society of Cardiology; 2012.
- Cohen AT, Agnelli G, Anderson FA, et al. Venous thromboembolism (VTE) in Europe—the number of VTE events and associated morbidity and mortality. Thrombosis and Haemostasis. 2007;98(4):756–764.
- Rapold HJ. Promotion of thrombin activity by thrombolytic therapy without simultaneous anticoagulation. The Lancet. 1990;335(8687):481–482.
- Serizawa K, Urano T, Kozima Y, Takada Y, Takada A. The potential role of platelet PAI-1 in t-PA mediated clot lysis of platelet rich plasma. Thrombosis Research. 1993;71(4):289–300.
- Ghandehari K. Barriers of thrombolysis therapy in developing countries. Stroke Research and Treatment. 2011;2011:4 pages.686797
- Bokarewa MI, Jin T, Tarkowski A. Staphylococcus aureus: staphylokinase. International Journal of Biochemistry and Cell Biology. 2006;38(4):504–509.
- Wu SC, Castellino FJ, Wong SL. A fast-acting, modular-structured staphylokinase fusion with Kringle-1 from human plasminogen as the fibrin-targeting domain offers improved clot lysis efficacy. The Journal of Biological Chemistry. 2003;278(20):18199–18206.
- Szarka SJ, Sihota EG, Habibi HR, Wong S. Staphylokinase as a plasminogen activator component in recombinant fusion proteins. Applied and Environmental Microbiology. 1999;65(2):506–513.
- Miele RG, Prorok M, Costa VA, Castellino FJ. Glycosylation of asparagine-28 of recombinant staphylokinase with high-mannose-type oligosaccharides results in a protein with highly attenuated plasminogen activator activity. The Journal of Biological Chemistry. 1999;274(12):7769–7776.
- Sakharov DV, Lijnen HR, Rijken DC. Interactions between staphylokinase, plasmin(ogen), and fibrin. Staphylokinase discriminates between free plasminogen and plasminogen bound to partially degraded fibrin. The Journal of Biological Chemistry. 1996;271(44):27912–27918.
- Yamada T, Shimada Y, Kikuchi M. Integrin-specific tissue-type plasminogen activator engineered by introduction of the Arg-Gly-Asp sequence. Biochemical and Biophysical Research Communications. 1996;228(2):306–311.
- Pal Y, Gupta JC, Mukherjee KJ. Optimizing recombinant protein expression in the T7 system under the control of the proUp promoter. Biotechnology Letters. 2001;23(1):41–46.
- Gowrishankar J, Manna D. How is osmotic regulation of transcription of the Escherichia coli proU operon achieved? A review and a model. Genetica. 1996;97(3):363–378.
- Choi B, Bobrowicz P, Davidson RC, et al. Use of combinatorial genetic libraries to humanize N-linked glycosylation in the yeast Pichia pastoris . Proceedings of the National Academy of Sciences of the United States of America. 2003;100(9):5022–5027.
- Cregg JM, Vedvick TS, Raschke WC. Recent advances in the expression of foreign genes in Pichia pastoris . Bio/Technology. 1993;11(8):905–910.
- Bhandari P, Gowrishankar J. An Escherichia coli host strain useful for efficient overproduction of cloned gene products with NaCl as the inducer. Journal of Bacteriology. 1997;179(13):4403–4406.
- Szemraj J, Walkowiak B, Kawecka I, et al. A new recombinant thrombolytic and antithrombotic agent with higher fibrin affinity—a staphylokinase variant. I. In vitro study. Journal of Thrombosis and Haemostasis. 2005;3(10):2156–2165.
- Kowalski M, Brown G, Bieniasz M, et al. Cloning and expression of a new recombinant thrombolytic and anthithrombotic agent—a staphylokinase variant. Acta Biochimica Polonica. 2009;56(1):41–53.
- Wang M, Wang Y, Wang J, et al. Construction and characterization of a novel staphylokinase variant with thrombin-inhibitory activity. Biotechnology Letters. 2009;31(12):1923–1927.
- Thrombogenics NV. 2012,
- Pulicherla KK, Gadupudi GS, Rekha VPB, Seetharam K, Kumar A, Rao KRSS. Isolation, cloning and expression of mature staphylokinase from lysogenic Staphylococcus aureus collected from a local wound sample in a salt inducible E. coli expression host. International Journal of Advanced Science and Technology. 2011;30:35–42.
- Sambrook J, Russel DW. Molecular Cloning: A Laboratory Manual. New York, NY, USA: Cold Spring Harbor Laboratory Press; 2001.
- Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970;227(5259):680–685.
- Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. The Journal of Biological Chemistry. 1951;193(1):265–275.
- Devriese LA, van de Kerckhove A. A comparison of methods used for testing staphylokinase (fibrinolysin) production in Staphylococcus strains. Antonie van Leeuwenhoek. 1980;46(5):457–465.
- Astrup T, Stendorff I. A fibrinolytic system in human milk. Proceedings of the Society for Experimental Biology and Medicine. 1953;84(3):605–608.
- Bi Q, Cen X, Huang Y, Zhu S. Construction and characterization of trifunctional single-chain urokinase-type plasminogen activators. Trifunctional plasminogen activators. European Journal of Biochemistry. 2002;269(6):1708–1713.
- Trieu T, Behnke D, Gerlach D, Tang J. Activation of human plasminogen by recombinant staphylokinase. Methods in Enzymology. 1993;223:156–167.
- Jackson KW, Esmon N, Tang J. Streptokinase and staphylokinase. Methods in Enzymology. 1981;80:387–394.
- Schlott B, Gührs KH, Hartmann M, Röcker A, Collen D. Staphylokinase requires NH2-terminal proteolysis for plasminogen activation. The Journal of Biological Chemistry. 1997;272(9):6067–6072.
- Collen D, Schlott B, Engelborghs Y, et al. On the mechanism of the activation of human plasminogen by recombinant staphylokinase. The Journal of Biological Chemistry. 1993;268(11):8284–8289.
- Lacoste E, Martineau I, Gagnon G. Platelet concentrates: effects of calcium and thrombin on endothelial cell proliferation and growth factor release. Journal of Periodontology. 2003;74(10):1498–1507.
- Zhang L, Wang J, Yu M, Ru B. Functional properties of a recombinant chimeric plasminogen activator with platelet-targeted fibrinolytic and anticoagulant potential. Molecular Genetics and Metabolism. 2004;82(4):304–311.
- Challen A, Branch WJ, Cummings JH. Quantitation of platelet mass during aggregation in the electronic (wellcome) whole blood aggregometer. Journal of Pharmacological Methods. 1982;8(2):115–122.
- Maraganore JM, Adelman BA. Hirulog: a direct thrombin inhibitor for management of acute coronary syndromes. Coronary Artery Disease. 1996;7(6):438–448.
Source: PubMed